Alpha 2.0
Login Register
» Articles » PMID: 37426424

Editorial: Cancer Treatment and Early Detection Targeting HER Receptors, Volume II

Overview
Journal Front Mol Biosci
Specialty Biology
Date 2023 Jul 10
PMID 37426424
Authors
Xiaoqing Cai
Libing Zhang
Shengxi Chen
Affiliations
Soon will be listed here.
Citing Articles

Editorial: New strategies for reversing cancer therapy resistance.

Du Y, Liu X, Wang L, Chen S Front Pharmacol. 2024; 15:1411519.

PMID: 38698819 PMC: 11063769. DOI: 10.3389/fphar.2024.1411519.

References
1.
Oh D, Bang Y . HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2019; 17(1):33-48. DOI: 10.1038/s41571-019-0268-3. View
2.
Olivier T, Prasad V . Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines. Transl Oncol. 2022; 23:101475. PMC: 9256830. DOI: 10.1016/j.tranon.2022.101475. View
3.
Zhang C, Han M, Zhang F, Yang X, Du J, Zhang H . Enhancing Antitumor Efficacy of Nucleoside Analog 5-Fluorodeoxyuridine on HER2-Overexpressing Breast Cancer by Affibody-Engineered DNA Nanoparticle. Int J Nanomedicine. 2020; 15:885-900. PMC: 7020921. DOI: 10.2147/IJN.S231144. View
4.
El-Gamal M, Mewafi N, Abdelmotteleb N, Emara M, Tarazi H, Sbenati R . A Review of HER4 (ErbB4) Kinase, Its Impact on Cancer, and Its Inhibitors. Molecules. 2021; 26(23). PMC: 8659013. DOI: 10.3390/molecules26237376. View
5.
Cai X, Zhang L, Chen S . Editorial: Cancer Treatment and Early Detection Targeting HER Receptors. Front Mol Biosci. 2022; 9:940055. PMC: 9240762. DOI: 10.3389/fmolb.2022.940055. View